MX370732B - Método in vitro para determinar la estabilidad de composiciones que comprenden receptores fc-gamma solubles. - Google Patents
Método in vitro para determinar la estabilidad de composiciones que comprenden receptores fc-gamma solubles.Info
- Publication number
- MX370732B MX370732B MX2016001288A MX2016001288A MX370732B MX 370732 B MX370732 B MX 370732B MX 2016001288 A MX2016001288 A MX 2016001288A MX 2016001288 A MX2016001288 A MX 2016001288A MX 370732 B MX370732 B MX 370732B
- Authority
- MX
- Mexico
- Prior art keywords
- gamma receptor
- stability
- iiia
- determining
- human
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
La presente invención se refiere a un método in vitro para determinar la estabilidad de una composición que comprende o que consiste esencialmente del receptor Fc gama IIA, IIB, IIIA y/o IIIB, humano, soluble, dicho método comprende los pasos de: (a) poner en contacto una superficie que comprende el receptor Fc gamma IIA, IIB, IIIA y/o IIIB humano, con una cantidad establecida de IgG humana, agregada; (b) poner en contacto dicha superficie que comprende el receptor Fc gamma IIA, IIB, IIIA y/o IIIB humano, con una cantidad establecida de dicha composición del receptor Fc gamma IIA, IIB, IIIA y/o IIIB, humano soluble ; y (c) determinar la cantidad de IgG humana agregada que se une a dicha superficie que comprende dicho receptor Fc gamma IIA, IIB, IIIA y/o IIIB, humano, (d) y comparar la cantidad de IgG humana agregada que se une a dicha superficie como se determina en el paso (c) con un valor de referencia y determinar de este modo la estabilidad de dicha composición que comprende o consiste esencialmente del receptor Fc gamma IIA, IIB, IIIA y/o IIIB, humano soluble.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003835.9A EP2833139A1 (en) | 2013-08-01 | 2013-08-01 | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| PCT/EP2014/066646 WO2015015001A1 (en) | 2013-08-01 | 2014-08-01 | In vitro method for determining the stability of compositions comprising soluble fc gamma receptor(s) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001288A MX2016001288A (es) | 2016-07-07 |
| MX370732B true MX370732B (es) | 2019-12-20 |
Family
ID=48917312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001288A MX370732B (es) | 2013-08-01 | 2014-08-01 | Método in vitro para determinar la estabilidad de composiciones que comprenden receptores fc-gamma solubles. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10866247B2 (es) |
| EP (2) | EP2833139A1 (es) |
| JP (2) | JP6697385B2 (es) |
| KR (1) | KR102282823B1 (es) |
| CN (1) | CN105593685B (es) |
| AU (1) | AU2014298371B2 (es) |
| BR (1) | BR112016001898A2 (es) |
| CA (1) | CA2919997C (es) |
| EA (1) | EA030087B1 (es) |
| ES (1) | ES2687716T3 (es) |
| IL (1) | IL243861B (es) |
| MX (1) | MX370732B (es) |
| SG (1) | SG11201600706PA (es) |
| WO (1) | WO2015015001A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2833139A1 (en) | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| DE10157290A1 (de) | 2001-11-22 | 2003-06-05 | Max Planck Gesellschaft | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
| EP1664119A1 (en) | 2003-09-08 | 2006-06-07 | Medical Research Council | Method for the treatment or prophylaxis of tuberculosis |
| US8354109B2 (en) * | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| BRPI0712232A2 (pt) * | 2006-06-02 | 2012-01-10 | Koninkl Philips Electronics Nv | dispositivo de detecção, e, método para detectar pelo menos um analito em pelo menos uma amostra |
| EP1870422A1 (en) * | 2006-06-20 | 2007-12-26 | SuppreMol GmbH | Means for the treatment of diseases characterized by an excessive immune reaction |
| CN102574912B (zh) * | 2009-09-29 | 2014-12-24 | 弗·哈夫曼-拉罗切有限公司 | 缓冲溶质的过滤前调节 |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| US20130289247A1 (en) | 2010-11-01 | 2013-10-31 | Dsm Ip Assets B.V. | Single unit ion exchange chromatography antibody purification |
| CN103105326A (zh) * | 2012-12-30 | 2013-05-15 | 上海市内分泌代谢病研究所 | 一种Th细胞表面及胞内染色的方法及其应用 |
| EP2833139A1 (en) | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
-
2013
- 2013-08-01 EP EP13003835.9A patent/EP2833139A1/en not_active Withdrawn
-
2014
- 2014-08-01 KR KR1020167005136A patent/KR102282823B1/ko active IP Right Grant
- 2014-08-01 US US14/909,009 patent/US10866247B2/en active Active
- 2014-08-01 BR BR112016001898A patent/BR112016001898A2/pt not_active Application Discontinuation
- 2014-08-01 CA CA2919997A patent/CA2919997C/en active Active
- 2014-08-01 MX MX2016001288A patent/MX370732B/es active IP Right Grant
- 2014-08-01 CN CN201480054299.7A patent/CN105593685B/zh active Active
- 2014-08-01 JP JP2016530549A patent/JP6697385B2/ja not_active Expired - Fee Related
- 2014-08-01 EP EP14755788.8A patent/EP3028041B1/en active Active
- 2014-08-01 ES ES14755788.8T patent/ES2687716T3/es active Active
- 2014-08-01 SG SG11201600706PA patent/SG11201600706PA/en unknown
- 2014-08-01 WO PCT/EP2014/066646 patent/WO2015015001A1/en active Application Filing
- 2014-08-01 EA EA201690319A patent/EA030087B1/ru not_active IP Right Cessation
- 2014-08-01 AU AU2014298371A patent/AU2014298371B2/en active Active
-
2016
- 2016-01-31 IL IL243861A patent/IL243861B/en active IP Right Grant
-
2019
- 2019-08-22 JP JP2019151958A patent/JP2020000244A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL243861A0 (en) | 2016-04-21 |
| JP2016525364A (ja) | 2016-08-25 |
| CA2919997C (en) | 2021-11-02 |
| MX2016001288A (es) | 2016-07-07 |
| JP2020000244A (ja) | 2020-01-09 |
| EA030087B1 (ru) | 2018-06-29 |
| JP6697385B2 (ja) | 2020-05-20 |
| KR102282823B1 (ko) | 2021-07-29 |
| BR112016001898A2 (pt) | 2017-09-05 |
| IL243861B (en) | 2019-06-30 |
| EP2833139A1 (en) | 2015-02-04 |
| CN105593685B (zh) | 2017-11-24 |
| ES2687716T3 (es) | 2018-10-26 |
| CN105593685A (zh) | 2016-05-18 |
| US20160195541A1 (en) | 2016-07-07 |
| EP3028041A1 (en) | 2016-06-08 |
| US10866247B2 (en) | 2020-12-15 |
| EP3028041B1 (en) | 2018-07-18 |
| AU2014298371A1 (en) | 2016-02-18 |
| CA2919997A1 (en) | 2015-02-05 |
| KR20160036058A (ko) | 2016-04-01 |
| EA201690319A1 (ru) | 2016-06-30 |
| AU2014298371B2 (en) | 2020-05-07 |
| WO2015015001A1 (en) | 2015-02-05 |
| SG11201600706PA (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200213A1 (ar) | جزيئات رابطة لـ pd-1 وطرق استخدامها | |
| MX2021013681A (es) | Moleculas de union a lag-3 y metodos de uso de las mismas. | |
| PH12017500402A1 (en) | Anti-glucagon antibodies and uses thereof | |
| EP3421495A3 (en) | Modulation of t cells with bispecific antibodies and fc fusions | |
| SA518400491B1 (ar) | نظير إنسولين جديد واستخدامه | |
| EA201591546A1 (ru) | Мультивалентные и моновалентные мультиспецифические комплексы и их применение | |
| CU20130023A7 (es) | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| MX2016011898A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
| EA201401204A1 (ru) | Антитела к il-23p19 | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| NZ700933A (en) | Modeling compounds and methods of making and using the same | |
| MX2016010729A (es) | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. | |
| EA201500604A1 (ru) | Пленочная лекарственная форма, содержащая свободное основание силденафила, и способ ее получения | |
| MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
| MX2023009584A (es) | Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos. | |
| MX2016001288A (es) | Metodo in vitro para determinar al estabilidad de composiciones que comprenden receptores fc-gamma solubles. | |
| WO2016049522A3 (en) | Compositions comprising ch505 envelopes, and trimers | |
| MX2014013049A (es) | Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante. | |
| TW201613620A (en) | Jelly-like medicinal composition of potassium iodide | |
| RS54013B1 (en) | HIGH-ELASTIC GELS IN OPTAMOLOGICAL SURGERY | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| CL2016001035A1 (es) | Procedimiento para mejorar la capacidad de almacenamiento de semillas | |
| WO2015166355A3 (en) | Targeted therapy to restore radioactive iodine transport in thyroid cancer | |
| MX2016016525A (es) | Cinematizacion de salida en un ambiente de dispositivo compuesto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |